Reasonable therapy for bronchial asthma: single inhaler strategy


DOI: https://dx.doi.org/10.18565/pharmateca.2019.5.70-78

S.L. Babak, M.V. Gorbunova, A.G. Malyavin

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Department of Phthisiology and Pulmonology, Moscow, Russia
Background. Therapy of patients with bronchial asthma (BA) depends on a variety of multidirectional factors, such as the phenotype of the disease, severity, the presence of concomitant diseases, the response to therapy. There are two most discussed main strategies: regular BA treatment with an established dose with stepwise correction (step up/down) or a single inhaler strategy with “quantum satis” dosing.
The purpose of this publication is to present a new strategy and modern approaches for the reasonable treatment of BA with a single inhaler (fixed combination of budesonide/formoterol in the “turbuhaler” device) with the possibility of its implementation in actual clinical practice.
Conclusion. In real clinical practice, therapy of asthma patient should not face serious difficulties of execution, if the practitioner has modern capabilities of combined pharmacotherapy and non-drug correction methods, and is able to successfully plan a therapeutic strategy. A modern rational therapeutic strategy for treating patients with asthma should recognize the reasonable dosing of fixed BUD/ FOR combinations in a single inhaler mode. The priority doctrine of treating patients with asthma should be “quantum satis” therapy, which allows achieving a long-lasting, positive effect.
Keywords: bronchial asthma, single inhaler strategy, budesonide/formoterol, GINA, quantum satis strategy

About the Autors


Corresponding author: Sergey L. Babak, MD, Professor, Department of Phthisiology and Pulmonology, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia; e-mail: sergbabak@mail.ru
Address: 20, Build. 1, Delegatskaya Street, Moscow 127473, Russian Federation


Бионика Медиа